De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.

被引：0
|
作者：
Goldvaser, Hadar
Yasmin, Korzets Ceder
Shepshelovich, Daniel
Yerushalmi, Rinat
Sarfaty, Michal
Ribnikar, Domen
Thavendiranathan, Paaladinesh
Amir, Eitan
机构：
[1] Beilinson Med Ctr, Davidoff Ctr, Rabin Med Ctr, Kyriat Ono, Israel
[2] Beilinson Hosp 32393 Shem, Petah Tiqwa, Israel
[3] Rabin Med Ctr, Petah Tiqwa, Israel
[4] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[5] Davidoff Canc Ctr, Petah Tiqwa, Israel
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
524
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
    Nixon, N. A.
    Hannouf, M. B.
    Verma, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 89 : 72 - 81
  • [32] Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)
    Lin, N.
    Danso, M. A.
    David, A. K.
    Muscato, J.
    Rayson, D.
    Houck, W. A., III
    Ellis, C.
    DeSilvio, M.
    Garofalo, A.
    Nagarwala, Y.
    Winer, E.
    CANCER RESEARCH, 2012, 72
  • [33] Clinical impact of epidermal growth factor receptor (EGFR) coexpression in early breast cancer with human epidermal growth factor receptor 2 (HER2) overexpression
    Park, S.
    Cho, E.
    Shin, Y.
    Hong, S.
    Lee, M.
    Park, Y.
    Nam, S.
    Yang, J.
    Choi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    Lluch-Gomez, J.
    Nunez-Alvarez, V.
    de la Torre-Hita, C.
    Bernal-Gomez, M.
    Campini-Bermejo, A.
    Perdomo-Zaldivar, E.
    Rodriguez-Perez, L.
    Calvete-Candenas, J.
    Martinez-Bautista, M. J.
    Benitez-Rodriguez, E.
    Baena-Canada, J. M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [35] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    J. Lluch-Gómez
    V. Núñez-Álvarez
    C. de la Torre-Hita
    M. Bernal-Gómez
    A. Campini-Bermejo
    E. Perdomo-Zaldívar
    L. Rodríguez-Pérez
    J. Calvete-Candenas
    M. J. Martínez-Bautista
    E. Benítez-Rodríguez
    J. M. Baena-Cañada
    Scientific Reports, 13
  • [36] Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient
    Freedman, Rachel A.
    Muss, Hyman B.
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 2 - 7
  • [37] Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan
    Nusawat, Chanon
    Sato, So
    Watanabe, Hideaki
    Konishi, Takaaki
    Yamana, Hayato
    Yasunaga, Hideo
    CLINICAL DRUG INVESTIGATION, 2024, 44 (12) : 927 - 938
  • [38] Predictive markers for trastuzumab-associated cardiac dysfunction in patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab
    Altundag, Kadri
    JOURNAL OF BUON, 2017, 22 (03): : 801 - 801
  • [39] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
  • [40] Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer
    Wong, Nan Soon
    Ang, Peter
    Dent, Rebecca
    Lee, Soo Chin
    Lim, Siew Eng
    Khoo, Kei Siong
    Ng, Raymond
    Shih, Vivianne
    Tan, Sing Huang
    Wong, Karmen
    Yap, Yoon Sim
    Shang, Yeap
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2015, 44 (10) : 360 - 367
12345